Laser Photonics Corp

S-11 forms-1.htm S-1

As filed with the Securities and Exchange Commission on July 30, 2026

Registration statement ** No. 333-_______**

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

(Exact name of Registrant as specified in its charter)

250 Technology Park

Lake Mary, FL 32746

(407) 804-1000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Ann Tewari, Interim President

Ralph Venegas, Acting CFO

250 Technology Park

Lake Mary, FL 32746

(407) 804-1000

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Ernest M. Stern, Esq.

CM Law LLP

1701 Pennsylvania Ave., N.W.

Suite. 200

Washington, D. C. 20006

(202) 580-6500

Approximate Date of Proposed Sale to the Public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☒

This Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the commission, acting pursuant to said Section 8(a), may determine.

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION, DATED JULY 30, 2026

Up to 800,000 Shares of Common Stock Underlying the Series A-7 Warrants

Up to 4,257,144 Shares of Common Stock Underlying the Series A-8 Warrants

Up to 234,058 Shares of Common Stock Underlying the Placement Agent Warrants

This prospectus relates to the offer and resale by the selling stockholders (the “Selling Stockholders”) identified herein of an aggregate of up to 5,234,144 shares (the “Shares”), of common stock, par value $0.001 per share (“Common Stock”), of Laser Photonics Corporation (the “Company”, “we”, “us” or “our”), that consists of (a) an aggregate of 5,057,144 shares of Common Stock underlying the Series A-7 and Series A-8 Warrants issued under the terms of a July 16, 2026, warrant inducement agreement (the “Warrant Inducement Agreement”) among the Company and certain existing warrant holders (the “Common Warrants”) and (b) an aggregate of 234,058 shares of Common Stock that are issuable upon exercise of certain placement agent warrants (the “Placement Agent Warrants”) issued to designees (or their assignees) of H.C. Wainwright & Co., LLC, the placement agent in connection with the Warrant Inducement Agreement transaction (“Wainwright” or the “Placement Agent”), pursuant to an engagement letter between us and Wainwright, in connection with the Warrant Inducement Agreement, and warrants issued to designees (or their assignees) of Wainwright in connection with the Notes (as such term is defined elsewhere in this prospectus). The Common Warrants and the Placement Agent Warrants collectively referred to as the “Warrants”.

The Shares will be resold from time to time by the Selling Stockholders listed in the section titled “Selling Stockholders” beginning on page 10.

The Selling Stockholders, or their respective transferees, pledgees, assignees, donees or other successors-in-interest, will sell the Shares through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The Selling Stockholders may sell any, all or none of the Shares offered by this prospectus, and we do not know when or in what amount the Selling Stockholders may sell their Shares hereunder following the effective date of this registration statement. We provide more information about how a Selling Stockholder may sell its Shares in the section titled “Plan of Distribution” on page 16.

We are registering the Shares on behalf of the Selling Stockholders, to be offered and sold by them from time to time. While we will not receive any proceeds from the sale of the Shares by the Selling Shareholders, we may receive cash proceeds equal to the total exercise price of the Common Warrants and the Placement Agent Warrants to the extent that the Common Warrants or Placement Agent Warrants are exercised for cash. However, we cannot predict when and in what amounts or if the Warrants will be exercised for cash, and it is possible that the Warrants may expire and never be exercised or be exercised, if at all, only on a cashless basis, in which each case we would not receive any cash proceeds. We have agreed to bear all of the expenses incurred in connection with the registration of the Shares. The Selling Stockholders will pay or assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of the Shares.

The Warrants offered hereby will have an exercise price of $0.975 per share and will be exercisable upon issuance of the Series A-7 and A-8 warrants (the “Initial Exercise Date”). The Series A-7 warrants will expire five years after the effective date of this registration statement, and the Series A-8 warrants will expire 24 months after the effective date of this registration statement. The exercise price and number of shares of our Common Stock issuable under the Common Warrants and Placement Agent Warrants are subject to customary adjustments as described in the Common Warrants and Placement Agent Warrants.

Our Common Stock trades on the Nasdaq Capital Market (“Nasdaq”) under the symbol “LASE”. On July 28, 2026, the last reported sales price of our Common Stock was $0.96 per share.

We are an “emerging growth company” as defined under the federal securities laws, and, as such, we have elected to comply with reduced reporting requirements for this prospectus and may elect to do so in future filings.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 10 of this prospectus to read about factors you should consider before investing in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is ______ __, 2026

TABLE OF CONTENTS

i